Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 10/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.41 |
| ▸ | HTR1A | P08908 | 7/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.36 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9041147 | 0.98 | SLC6A2 (0.40) | SLC6A2SLC6A3SLC6A4HTR1AMKNK1 | |
| SCHEMBL20002871 | 0.89 | HTR6 (0.36) | SLC6A2SLC6A3SLC6A4HTR1A | |
| Trifluoroacetic Acid SCHEMBL4771690 | 0.87 | PRCP (0.39) | SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL5214386 | 0.81 | SLC6A4 (0.33) | SLC6A4 | |
| SCHEMBL10795562 | 0.81 | SLC18A3 (0.45) | SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL15232332 | 0.79 | SLC6A2 (0.38) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL10663730 | 0.78 | MKNK1 (0.37) | SLC6A2SLC6A3SLC6A4HTR1AMKNK1 | |
| SCHEMBL28867235 | 0.76 | SLC6A2 (0.46) | SLC6A2SLC6A3SLC6A4HTR1A | |
| SCHEMBL17373707 | 0.76 | ADRB1 (0.45) | SLC6A3HTR1A | |
| SCHEMBL7800906 | 0.75 | SLC6A2 (0.42) | SLC6A2SLC6A3SLC6A4HTR1AMKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713634-B2 | SEROTONIN RECEPTOR ANTAGONIST | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2004-03-30 | — | — | US | disclosed |
| US-6664251-B2 | Serotonin receptor antagonist; treating cardiovascular disorder | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2003-12-16 | — | — | US | disclosed |
| US-20030166926-A1 | Pyrroloazepine derivatives | SUNTORY LIMITED (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-0686632-B1 | BENZOTHIAZINE DERIVATIVE | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-08-06 | — | — | EP | disclosed |
| US-20030078256-A1 | Benzothiazine derivative | SUNTORY LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-0557526-B1 | PYRROLOAZEPINE COMPOUND | SUNTORY LTD (JP) | 2003-04-02 | — | — | EP | disclosed |
| EP-0749967-B1 | Substituted benzothiazine derivative | SUNTORY LTD (JP) | 2003-01-22 | — | — | EP | disclosed |
| EP-0915881-B1 | PYRROLOAZEPINE COMPOUNDS | SUNTORY LTD (JP) | 2003-01-08 | — | — | EP | disclosed |
| US-6489473-B2 | FOR THERAPY AND PROPHYLAXIS OF ISCHEMIC HEART DISEASES SUCH AS ANGINA PECTORIS, ARRHYTHMIA, MYOCARDIAL INFARCTION, CONGESTIVE HEART FAILURE, CEREBRAL INFARCTION AND CEREBRAL SEQUELAE AFTER SUBARACHNOID HEMORRHAGE, HYPERTENSION | SUNTORY LIMITED (JP) | 2002-12-03 | — | — | US | disclosed |
| CN-1094126-C | Pyrroloazepine compounds | SUNTORY LTD (JP) | 2002-11-13 | — | — | CN | disclosed |
| EP-0749967-A1 | Substituted benzothiazine derivative | SUNTORY LIMITED (JP) | 1996-12-27 | — | — | EP | disclosed |
| EP-0749971-A1 | Thiopyran derivatives | SUNTORY LIMITED (JP) | 1996-12-27 | — | — | EP | disclosed |
| CN-1119859-A | benzothiazine derivatives | SUNTORY LTD (JP) | 1996-04-03 | — | — | CN | disclosed |
| EP-0441349-B1 | Pyrroloazepine derivatives | SUNTORY LTD (JP) | 1996-01-03 | — | — | EP | disclosed |
| EP-0686632-A1 | BENZOTHIAZINE DERIVATIVE | SUNTORY LIMITED (JP) | 1995-12-13 | — | — | EP | disclosed |
| US-5416082-A | Antiserotonine agents | SUNTORY LIMITED (JP) | 1995-05-16 | — | — | US | disclosed |
| US-5399557-A | Cardiovascular disorders | SUNTORY LIMITED (JP) | 1995-03-21 | — | — | US | disclosed |
| US-5391731-A | Useful therapeutics for circulatory diseases | SUNTORY LIMITED (JP) | 1995-02-21 | — | — | US | disclosed |
| EP-0557526-A1 | PYRROLOAZEPINE COMPOUND | SUNTORY LIMITED (JP) | 1993-09-01 | — | — | EP | disclosed |
| US-5206239-A | Cardiovascular disorders | SUNTORY LIMITED (JP) | 1993-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166926-A1 | Pyrroloazepine derivatives | TPH2, HTR2A, HTR2C | SLC6A2 140/4885SLC6A3 286/4885SLC6A4 24/4885 |
| US-20030078256-A1 | Benzothiazine derivative | TPH2, ADRB2, TPH1 | SLC6A2 356/4885SLC6A3 1316/4885SLC6A4 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.